In the context of wild-type EGFR NSCLC cells, the synergism between EGFR inhibition (using gefitinib) and PLK1 inhibitors was shown in the context of paclitaxel-resistance, and a cetuximab-conjugated nanoparticle delivering PLK1 siRNA was also shown to sensitize NSCLC cells to radiotherapy [11,12]. Here, EGFR is linked to non-small cell lung carcinoma.